Qulipta is owned by Abbvie Inc.
Qulipta contains Atogepant.
Qulipta has a total of 4 drug patents out of which 0 drug patents have expired.
Qulipta was authorised for market use on 28 September, 2021.
Qulipta is available in tablet;oral dosage forms.
Qulipta can be used as preventive treatment of episodic migraine in adults.
Drug patent challenges can be filed against Qulipta from September, 2025.
The generics of Qulipta are possible to be released after 30 January, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9499545||ABBVIE INC||Piperidinone carboxamide azaindane CGRP receptor antagonists|| |
(8 years from now)
|US8754096||ABBVIE INC||Piperidinone carboxamide azaindane CGRP receptor antagonists|| |
(9 years from now)
|US9850246||ABBVIE INC||Process for making CGRP receptor antagonists|| |
(10 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10117836||ABBVIE INC||Tablet formulation for CGRP active compounds|| |
(12 years from now)
|New Chemical Entity Exclusivity (NCE)||Sep 28, 2026|
NCE-1 date: September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic